Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q.M. Chow, Tanguy Y. Seiwert, Robert I. Haddad et al.|Journal of Clinical Oncology|2016Cited by 859
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, John Bridgewater, Li‐Tzong Chen et al.|New England Journal of Medicine|2023Cited by 530
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim resultsChristine D. Palmer, Karin Jooss, Amy Rappaport et al.|Nature Medicine|2022Cited by 225
Circulating Tumor DNA Profiling of Advanced Biliary Tract CancersKabir Mody, Mitesh J. Borad, Pashtoon Murtaza Kasi et al.|JCO Precision Oncology|2019Cited by 86
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.Ranee Mehra, Robert I. Haddad, Tanguy Y. Seiwert et al.|Journal of Clinical Oncology|2016Cited by 45